Central India Cancer Research Institute, Nagpur Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2008
NCT00824343
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Central India cancer Research Institute, Nagpur, India | Director and Onco-Surgeon, Central India Cancer Research Institute, Nagpur

Active Ingredients

Drugs in Phase 2 Trials (2)

gemcitabine (gemzar) (1 trial)

riviciclib (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Pancreatic Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2